Paul Matteis Analyst PerformanceManaging Director, Head of Therapeutics Research Biotechnology at Stifel NicolausPaul Matteis is a stock analyst at Stifel Nicolaus focused in the healthcare sector, covering 29 publicly traded companies. Over the past year, Paul Matteis has issued 47 stock ratings, including buy and hold recommendations. While full access to Paul Matteis' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Paul Matteis' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings95 Last 11 YearsBuy Recommendations76.47% 65 Buy RatingsCompanies Covered29 Unique Companies Ratings Distribution85RatingsDistribution of strong buy, buy, hold, and sell ratings by Paul Matteis.RatingPercentageCount Strong Buy0.0%0 ratings Buy76.5%65 ratings Hold23.5%20 ratings Sell0.0%0 ratingsOut of 85 total stock ratings issued by Paul Matteis at Stifel Nicolaus, the majority (76.5%) have been Buy recommendations, followed by 23.5% Hold.Best & Worst CallsBest Call0000.0%DYNJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ACADNov 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ29 companiesPaul Matteis, an analyst at Stifel Nicolaus, currently covers 29 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare28 companies96.6%Miscellaneous1 company3.4%Paul Matteis of Stifel Nicolaus specializes in stock coverage within the Healthcare sector, with additional focus on companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY17 companies58.6%PHARMACEUTICALS11 companies37.9%Miscellaneous1 company3.4% About Paul MatteisPaul Matteis joined Stifel in 2018. Based out of the firm’s Boston office, he serves as a Managing Director and Head of Biotech Research. Previously, Paul was a Senior Biotechnology Analyst covering small-cap and mid-cap companies at Leerink, with a focus on neuroscience, central nervous system and rare disease. Before this, he was a Research Assistant at the Harvard Division of Sleep Medicine at Brigham & Women’s Hospital. Paul was named a “Runner Up” in Small/Mid Cap Biotechnology in 2019-2024, as well as a “Rising Star” by Institutional Investor in both 2015 and 2016, as part of the publication’s All-America Research Team rankings. He attended Skidmore College in New York, where he studied Psychology and Pre-Medical Sciences and graduated Phi Beta Kappa.Follow on LinkedIn Paul Matteis' Ratings History at Stifel Nicolaus Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsKRSACyclerion Therapeutics9/14/2026Initiated Coverage$30.65$43.00Buy$0.0000.00% ROIBIIBBiogen9/10/2026Set Price Target$214.77$242.00$0.0000.00% ROILBRXLB Pharmaceuticals8/13/2026Set Price Target$44.87$53.00$0.0000.00% ROISIONSionna Therapeutics8/10/2026Reiterated Rating$4.19$7.00Hold$0.0000.00% ROINBIXNeurocrine Biosciences7/31/2026Boost Price Target$165.52$215.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/31/2026Lower Price Target$203.36$318.00Buy$0.0000.00% ROIACADACADIA Pharmaceuticals7/21/2026Boost Price Target$25.09$25.00Hold$0.0000.00% ROIALKSAlkermes7/20/2026Reiterated Rating$52.72$63.00Buy$0.0000.00% ROIDFTXDefinium Therapeutics7/8/2026Boost Price Target$44.48$60.00Buy$0.0000.00% ROICMPSCompass Pathways7/7/2026Boost Price Target$12.99$21.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. RYTMRhythm Pharmaceuticals6/15/2026Set Price Target$94.11$133.00$0.0000.00% ROIMPLTMaplight Therapeutics6/1/2026Boost Price Target$29.76$36.00Buy$0.0000.00% ROISPTXSeaport Therapeutics5/26/2026Initiated Coverage$17.50$30.00Buy$0.0000.00% ROISIONSionna Therapeutics5/18/2026Boost Price Target$40.22$55.00Buy$0.0000.00% ROIQUREuniQure5/5/2026Set Price Target$20.66$28.00$0.0000.00% ROIDFTXDefinium Therapeutics4/16/2026Set Price Target$22.46$30.00Buy$0.0000.00% ROIIMUXImmunic4/16/2026Set Price Target$10.00$25.00Buy$0.0000.00% ROILBRXLB Pharmaceuticals3/27/2026Boost Price Target$24.16$40.00Buy$0.0000.00% ROIKALVKalVista Pharmaceuticals3/26/2026Boost Price Target$17.49$42.00Buy$0.0000.00% ROIQUREuniQure3/2/2026Set Price Target$10.49$14.00$0.0000.00% ROIRYTMRhythm Pharmaceuticals2/26/2026Set Price Target$98.96$131.00$0.0000.00% ROIACADACADIA Pharmaceuticals2/26/2026Lower Price Target$25.05$24.00Hold$0.0000.00% ROIIONSIonis Pharmaceuticals2/26/2026Boost Price Target$81.57$77.00Hold$0.0000.00% ROIBMRNBioMarin Pharmaceutical2/24/2026Set Price Target$63.53$68.00$0.0000.00% ROIVRTXVertex Pharmaceuticals2/13/2026Boost Price Target$465.02$466.00Hold$0.0000.00% ROIBIIBBiogen2/6/2026Boost Price Target$201.18$214.00Buy$0.0000.00% ROIVTGNVistaGen Therapeutics12/17/2025Downgrade$0.79$1.00Hold$0.0000.00% ROIACADACADIA Pharmaceuticals12/16/2025Set Price Target$27.26$37.00$0.0000.00% ROIQUREuniQure12/11/2025Lower Price Target$20.14$40.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences12/11/2025Boost Price Target$155.63$188.00Buy$0.0000.00% ROILBRXLB Pharmaceuticals12/11/2025Boost Price Target$21.36$35.00Buy$0.0000.00% ROIDYNDyne Therapeutics12/11/2025Boost Price Target$19.69$39.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals12/11/2025Boost Price Target$404.46$508.00Buy$0.0000.00% ROIACADACADIA Pharmaceuticals12/11/2025Boost Price Target$26.81$25.00Hold$0.0000.00% ROIMPLTMaplight Therapeutics11/21/2025Initiated Coverage$13.29$28.00Buy$0.0000.00% ROIVTGNVistaGen Therapeutics11/17/2025Set Price Target$4.60$12.00$0.0000.00% ROINMRANeumora Therapeutics11/17/2025Boost Price Target$2.65$3.00Hold$0.0000.00% ROIBMRNBioMarin Pharmaceutical11/6/2025Reiterated Rating$52.80$61.00Hold$0.0000.00% ROIBIIBBiogen11/6/2025Upgrade$153.43$202.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals11/4/2025Lower Price Target$426.00$445.00Hold$0.0000.00% ROICODE RED: AI Meltdown Imminent? (Ad)After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.See the five simple steps to prepare before it's too lateNBIXNeurocrine Biosciences10/29/2025Boost Price Target$139.82$183.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical10/28/2025Lower Price Target$54.17$73.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals10/6/2025Boost Price Target$69.15$67.00Hold$0.0000.00% ROILBRXLB Pharmaceuticals10/6/2025Initiated Coverage$15.05$27.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals10/6/2025Boost Price Target$456.35$495.00Buy$0.0000.00% ROIPEPGPepGen9/25/2025Boost Price Target$5.87$12.00Buy$0.0000.00% ROIQUREuniQure9/24/2025Boost Price Target$46.06$65.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals8/5/2025Lower Price Target$472.27$455.00Hold$000.0000.00% ROINBIXNeurocrine Biosciences7/31/2025Boost Price Target$131.49$174.00Buy$000.0000.00% ROIDYNDyne Therapeutics7/31/2025Lower Price Target$9.90$36.00Buy$00.0000.00% ROIRYTMRhythm Pharmaceuticals5/29/2025Boost Price Target$62.66$94.00Buy$00.0000.00% ROIALNYAlnylam Pharmaceuticals3/31/2025Boost Price Target$268.46$345.00Buy$000.0000.00% ROINMRANeumora Therapeutics3/7/2025Downgrade$1.52$2.00Hold$0.0000.00% ROIRYTMRhythm Pharmaceuticals3/5/2025Initiated Coverage$54.02$78.00Buy$00.0000.00% ROISIONSionna Therapeutics3/4/2025Initiated Coverage$14.41$32.00Buy$00.0000.00% ROICMPSCompass Pathways2/27/2025Initiated Coverage$3.70$11.00Buy$0.0000.00% ROIGHRSGH Research2/27/2025Boost Price Target$10.82$32.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
